

18 Jan 2022 | Analysis

QUOTED. Scott Whitaker.

by

The US FDA and the medtech industry missed a 15 January deadline to send a user fee agreement to Congress, but AdvaMed CEO Scott Whitaker says he remains optimistic a deal will be reached soon.

“This past year has been challenging for FDA, and for all of us, frankly. So, these are different times and, as a result, have created new challenges. We, the medtech industry, are working through all these issues to better understand what the needs are going forward. The team at FDA is working hard alongside us to find consensus on several remaining issues – and I’m optimistic and confident that we will reach a resolution soon.” – Scott Whitaker, CEO, AdvaMed

- Find out more: [FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal](#)

[Click here](#) for a free trial of *Medtech Insight*